Abstract
Loss of gastrointestinal (GI) barrier integrity has been implicated in a wide range of inflammatory illnesses, including alcoholic cirrhosis. Using monolayers of Caco-2 (intestinal) cells as a model, we showed that the ability of ethanol (EtOH) to disrupt intestinal barrier integrity depends on damage to the microtubule (MT) cytoskeleton, especially oxidative injury. One drug that prevented both the MT damage and barrier disruption wasl-N6-1-iminoethyl-lysine, a selective inhibitor of the inducible form of nitric-oxide synthase (iNOS). Because of this finding and because overproduction of nitric oxide (NO) and generation of peroxynitrite (ONOO−) have been proposed to be responsible for mucosal injury in other GI disorders, we sought to determine whether NO overproduction and ONOO− formation mediates EtOH-induced MT damage and loss of intestinal barrier function. To this end, Caco-2 monolayers were exposed to EtOH or to authentic ONOO− or ONOO− generators with or without pretreatment with iNOS inhibitors or antioxidants. We found that EtOH caused 1) iNOS activation, 2) NO overproduction, 3) increases in oxidative stress and superoxide anion production (superoxide dismutase quenchable fluorescence of dichlorofluorescein), 4) nitration and oxidation of tubulin (immunoblotting), 5) decreased levels of stable polymerized tubulin, and 6) increased levels of disassembled tubulin. EtOH also 7) extensively damaged the MT cytoskeleton and 8) disrupted barrier function. Authentic ONOO− or ONOO− donors had similar effects. Pretreatment with a selective iNOS inhibitor,l-N6-1-iminoethyl-lysine, or with antioxidants (ONOO− scavengers urate orl-cysteine; superoxide anion scavenger superoxide dismutase) attenuated damage due to EtOH or to ONOO−generators. We conclude that EtOH-induced MT damage and intestinal barrier dysfunction require iNOS activation followed by NO overproduction and ONOO− formation. These findings provide a rationale for the development of novel therapeutic agents for alcohol-induced GI disorders that inhibit this mechanism.
Footnotes
-
Send reprint requests to: Ali Banan, Ph.D., Rush University Medical Center, Division of Digestive Diseases, 1725 W. Harrison, Suite 206, Chicago, IL 60612. E-mail: ali_banan{at}rush.edu
-
↵1 This work was supported in part by a grant from Rush University Medical Center. Portions of this work will be presented in the abstract form at the annual meeting of the American Gastroenterological Association in San Diego, CA, 2000.
- Abbreviations:
- GI
- gastrointestinal
- MT
- microtubule
- l-NIL
- l-N6-1-iminoethyl-lysine
- NO
- nitric oxide
- NOS
- nitric-oxide synthase
- iNOS
- inducible NOS
- EtOH
- ethanol
- EGF
- epidermal growth factor
- FSA
- fluorescein sulfonic acid
- SOD
- superoxide dismutase
- iSOD
- heat-inactivated SOD
- LSCM
- laser scanning confocal microscopy
- l-NNA
- NG-nitro-l-arginine
- HRP
- horseradish peroxidase
- l-Arg
- l-arginine
- l-NMMA
- NG-monomethyl-l-arginine
- DNP
- 2,4-dinitrophenylhydrazine
- DCF
- dichlorofluorescein
- DCFD
- 2′,7′-dichlorofluorescein diacetate
- X
- xanthine
- XO
- xanthine oxidase
- SIN-1
- 1,3-morpholinosydnonymine
- SNAP
- S-nitroso-N-acetyl penicillamine
- D-PBS
- Dulbecco's PBS
- Received February 9, 2000.
- Accepted May 31, 2000.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
